Publications
5808 Results
- Journal / Conference
- Blood 114:abst. #620, 2009 (ASH Annual Meeting, oral presentation)
- Year
- 2009
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
Accurate classification of diffuse large cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on formalin fixed paraffin embedded: a study from the Lymphoma and Leukemia Molecular Profiling Project
- Journal / Conference
- Blood 114:abst. #1948 (ASH Annual Meeting, poster presentation)
- Year
- 2009
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
High microvascular density correlates independently with poor outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus chemotherapy (R-CT)
- Journal / Conference
- Blood 114 abst. #2922 (ASH Annual Meeting, poster presentation)
- Year
- 2009
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
Chromosomal alterations in gene expression-defined pediatric aggressive B-cell non-hodgkin lymphomas (B-NHL)
- Journal / Conference
- Blood 114:abst. 1100 (ASH Annual Meeting, poster presentation)
- Year
- 2009
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
MYC translocations and expression are clinically important in R-CHOP treated patients with de novo DLBCL
- Journal / Conference
- Blood 114:abst. #790
- Year
- 2009
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Preliminary results of Southwest Oncology Group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to no additional therapy versus post-consolidation gemtuzumab ozogamicin for previously untreated acute myeloid leukemia
- Journal / Conference
- Journal of Clinical Oncology, 27(24):3881-3886
- Year
- 2009
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-9313
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status [PMC2734394; PMID19620488]
- Journal / Conference
- International Journal of Cancer 124(9)2082-2087
- Year
- 2009
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. PMC2682694;PMID: 19117055.
- Journal / Conference
- Prostate 69(12):1303-1311
- Year
- 2009
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Serum adiponectin, c-peptide and leptin and risk of symptomatic beign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Cancer 1154(16):3661-3669
- Year
- 2009
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Human Press, New York, NY, ch 7, pp 71-78
- Year
- 2009
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217